Unknown PHASE2 INTERVENTIONAL 1-arm NCT04004572

Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma

A Multi-center, Prospective Study of the Efficacy and Safety of PD-1 Antibody (Sintilimab) in Combination With Pegaspargase and Erlotinib in the Treatment of Stage IV Extranodal NK/T-cell Lymphoma Unfit for High-intensity Chemotherapy

Sponsor: Rong Tao

Conditions Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Interventions LEAP regimen

Updated 7 times since 2019 Last updated: Jan 27, 2021 Started: Jul 1, 2019 Primary completion: Dec 30, 2021 Completion: Dec 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, this trial is ongoing. The trial is conducted by Rong Tao and has accumulated 7 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Feb 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Feb 2021 — Feb 2023 [monthly]

Recruiting PHASE2
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Nov 2019 — Jan 2021 [monthly]

Recruiting PHASE2
Aug 2019 — Nov 2019 [monthly]

Recruiting PHASE2

First recorded

Jul 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rong Tao

Data source: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China